A new study shows that delivery of gene therapy to correct the gene mutations that cause CLN2 disease, or Batten disease, directly into the cerebrospinal fluid (CSF) has potential therapeutic effects.
SAN RAFAEL, Calif., June 1, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission (EC) has granted marketing authorization for Brineura™ (cerliponase ...
The Rich family have seen first hand how much the drug can help children with a devastating Batten disease diagnosis ...
LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 disease FDA designations underscore ...
A new study shows that delivery of gene therapy to correct the gene mutations that cause CLN2 disease, or Batten disease, directly into the cerebrospinal fluid (CSF) has potential therapeutic effects.
RGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of CLN2 disease, the most common form of Batten disease Patient dosed under a ...
Most people haven’t heard of the CLN2 Batten Disease, an illness that ravages the motor skills, speech and vision of its host. Those who have the illness – mostly children – have a greatly shortened ...
SAN RAFAEL, Calif., April 27, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results